Form 4: Akero Therapeutics Executive Catriona Yale Executes Stock Option and Sells Shares

Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 15, 2025, Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options to acquire 9,073 shares of common stock at a price of $21.10 per share.
• Yale then sold a total of 9,073 shares in two separate transactions.
• The first sale involved 7,873 shares at a weighted-average price of $37.803, with prices ranging from $37.37 to $38.30.
• The second sale involved 1,200 shares at a weighted-average price of $38.616, with prices ranging from $38.42 to $38.87.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• Following these transactions, Yale directly owns 95,034 shares of Akero Therapeutics common stock and holds options for 20,000 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives to have pre-arranged trading plans to sell shares over time.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged trading plan mitigates concerns about insider information.

Key Dates

Keywords

Akero Therapeutics, Catriona Yale, Stock Options, Share Sales, Form 4, Rule 10b5-1, Insider Trading